In a major success to beat corona, An Indian pharmaceutical company based at Hyderabad Bharat Biotech developed the first potential vaccine to treat COVID19. The company has been given a green signal from DCGI(Drug Controller General of India) to start the trial on humans. As per the company claim, the drug is under clinical trial and they received successful results in the preliminary stage. Joining hands with ICMR (Indian Council of Medical Research) and NIV(National Institute of Virology) was instrumental in the development of this vaccine as per the developers. The trial will start in the month of July.
About Bharat Biotech.
Bharat Biotech started operations in 1996—the year Dr. Krishna M. Ella and Mrs. Suchitra Ella returned from the US to set up a company dedicated to creating innovative vaccines and bio-therapeutics. Dr. Ella was returning from a research and teaching stint in the US and he wanted the new company to be an intellectual capital powerhouse. In the years that followed, he assembled a team of bright scientists and led the creation of path-breaking vaccines.
Today, Bharat Biotech has over 160 patents. As a leading biotechnology company, we seamlessly straddle the worlds of product research and manufacturing to create effective vaccines and therapeutics for patients around the world.
Bharat Biotech’s track record in developing Vero cell culture platform technologies has been proven in several vaccines for polio, rabies, rotavirus, Japanese Encephalitis, Chikungunya, and Zika.
According to the Health Ministry, India’s total coronavirus cases reached 5,48,318 as of Monday evening. Worldwide, the novel coronavirus has now claimed at least 501,847 lives and infected as many as 10,161,240 people.
